Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Platinum-Resistant Ovarian Carcinoma: early-phase trial registry
5 of 14 indexed Platinum-Resistant Ovarian Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 5 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Platinum-Resistant Ovarian Carcinoma: 14 US clinical trials tracked, 5 recruiting.
Platinum-Resistant Ovarian Carcinoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition platinum-resistant-ovarian-carcinoma
OPEN 5 | RECR 36% | LATE 0 | EARLY 14 | RANK #1230 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Attention (36% recruiting · 14 trials)
Platinum-Resistant Ovarian Carcinoma lists 5 open slots (36% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Platinum-Resistant Ovarian Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Platinum-Resistant Ovarian Carcinoma is recruiting below its size-band peers.
5 of 14 indexed trials (35.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Platinum-Resistant Ovarian Carcinoma research.
National Cancer Institute (NCI) accounts for 4 of 14 trials (28.6%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Platinum-Resistant Ovarian Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 38 among the 14 trials that report a genuine target (sentinel values excluded). 14 of those (100%) plan for fewer than 100 participants.
-
Platinum-Resistant Ovarian Carcinoma research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Ira Winer
NCT04055649
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Mayo Clinic
NCT05465941
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
City of Hope Medical Center
NCT05225363
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Emory University
NCT05998135
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
NCT06483048
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT03587311
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Precigen
NCT03907527
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT02298959
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
NCT01970722
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Floor Backes, MD
NCT04781088
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT03586661
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
NCT03449108
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
National Cancer Institute (NCI)
NCT04616534
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02898207
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Platinum-Resistant Ovarian Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Platinum-Resistant Ovarian Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Platinum-Resistant Ovarian Carcinoma page
14 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Platinum-Resistant Ovarian Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Platinum-Resistant Ovarian Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Platinum-Resistant Ovarian Carcinoma condition card totals 14 registered trials; most-linked intervention Paclitaxel; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.